The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada

References

• Barnett, B. S., W. O. Siu, and H. G. Pope. 2018. A survey of American psychiatrists’ attitudes toward classic hallucinogens. The Journal of Nervous and Mental Disease 206 (6):476–80. doi:10.1097/nmd.0000000000000828.
   PubMed Web of Science ®Google Scholar
• Boehnke, K. F., A. K. Davis, and J. McAfee. 2022. Applying lessons from cannabis to the psychedelic highway. JAMA Health Forum 3 (6):e221618. doi:10.1001/jamahealthforum.2022.1618.
   PubMedGoogle Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. R. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., S. Ross, S. Bhatt, T. Baron, A. A. Forcehimes, E. Laska, S. E. Mennenga, K. O’Donnell, L. T. Owens, S. Podrebarac et al. 2022. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 79(10):953–62. doi:10.1001/jamapsychiatry.2022.2096.
   PubMed Web of Science ®Google Scholar
• Canadian Alcohol and Drugs Survey (CADS). 2019. CADS Summary of Results for 2019 - Canada.Ca. https://www.canada.ca/en/health-canada/services/canadian-alcohol-drugs-survey/2019-summary.html#a4.
   Google Scholar
• Carhart-Harris, R. L., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384 (15):1402–11. doi:10.1056/nejmoa2032994.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32 (7):725–31. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• David, B., and D. J. Hellerstein. 2022. Assessing the risk–benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research. Psychopharmacology 239 (6):1907–32. doi:10.1007/s00213-021-06049-6.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., G. Agin-Liebes, M. España, B. Pilecki, and J. Luoma. 2021. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Journal of Psychoactive Drugs 54 (4):309–18. doi:10.1080/02791072.2021.1971343.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry 78 (5):481. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• Epstein, R. M., and R. L. Street. 2011. The values and value of patient-centered care. The Annals of Family Medicine 9 (2):100–03. doi:10.1370/afm.1239.
   PubMed Web of Science ®Google Scholar
• Fischer, B., Y. Murphy, K. Rudzinski, and D. MacPherson. 2016. Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. International Journal of Drug Policy 27:23–35. doi:10.1016/j.drugpo.2015.08.007.
   PubMed Web of Science ®Google Scholar
• Glynos, N. G., C. W. Fields, J. Barron, M. Herberholz, D. J. Kruger, and K. F. Boehnke. 2022. Naturalistic psychedelic use: A world apart from clinical care. Journal of Psychoactive Drugs 1–10. doi:10.1080/02791072.2022.2108356.
   Web of Science ®Google Scholar
• Goodwin, G. M., S. T. Aaronson, O. Alvarez, P. C. Arden, A. Baker, J. C. Bennett, C. Bird, R. E. Blom, C. Brennan, D. Brusch et al. 2022. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 387(18):1637–48. doi:10.1056/nejmoa2206443.
   PubMed Web of Science ®Google Scholar
• Haijen, E. C. H. M., M. Kaelen, L. Roseman, C. Timmermann, H. Kettner, S. Russ, D. Nutt, R. E. Daws, A. D. G. Hampshire, R. Lorenz, et al. 2018. Predicting responses to psychedelics: a prospective study. Frontiers in Pharmacology 9:897. doi:10.3389/fphar.2018.00897.
   PubMed Web of Science ®Google Scholar
• IBM Corp. 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.
   Google Scholar
• Jerome, L., A. A. Feduccia, J. B. Wang, S. Hamilton, B. Yazar-Klosinski, A. Emerson, M. C. Mithoefer, and R. Doblin. 2020. Long-term follow-up outcomes of MDMA-Assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of Six Phase 2 trials. Psychopharmacology 237 (8):2485–97. doi:10.1007/s00213-020-05548-2.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28 (11):983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2016. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):1–6. doi:10.3109/00952990.2016.1170135.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., R. R. Griffiths, P. S. Hendricks, and J. E. Henningfield. 2018. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology 142:143–66. doi:10.1016/j.neuropharm.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., W. A. Richards, and R. R. Griffiths. 2008. Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22 (6):603–20. doi:10.1177/0269881108093587.
   PubMed Web of Science ®Google Scholar
• Leor, R., D. J. Nutt, and R. L. Carhart-Harris. 2018. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology 8:974. doi:10.3389/fphar.2017.00974.
   PubMed Web of Science ®Google Scholar
• McCrae, K., S. Tobias, K. Tupper, J. Arredondo, B. Henry, S. Mema, E. Wood, and T. Lianping. 2019. Drug checking services at music festivals and events in a Canadian setting. Drug & Alcohol Dependence 205:107589. doi:10.1016/j.drugalcdep.2019.107589.
   PubMed Web of Science ®Google Scholar
• Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, G. Marcela Ot’alora, W. Garas, C. Paleos, I. Gorman, et al. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled Phase 3 study. Nature Medicine:1–9. doi:10.1038/s41591-021-01336-3.
   PubMed Web of Science ®Google Scholar
• Murphy, R., H. Kettner, R. Zeifman, B. Giribaldi, L. Kartner, J. Martell, T. Read, A. Murphy-Beiner, M. Baker-Jones, D. Nutt, et al. 2022. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Frontiers in Pharmacology 12:788155. doi:10.3389/fphar.2021.788155.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). 2022. Marijuana and hallucinogen use among young adults reached all-time high in 2021. https://www-nih-gov/news-events/news-releases/marijuana-hallucinogen-use-among-young-adults-reached-all-time-high-2021.
   Google Scholar
• Ng, J. Y., P. Homayouni, S. Usman, and Z. Gomes. 2022. The medical cannabis regulatory framework in Canada: A narrative review. European Journal of Integrative Medicine 50:102104. doi:10.1016/j.eujim.2022.102104.
   Web of Science ®Google Scholar
• Ofir, L., D. Shmulewitz, C. Walsh, and D. S. Hasin. 2022. Adolescent and adult time trends in US hallucinogen use, 2002–19: Any use, and use of ecstasy, LSD and PCP. Addiction 117 (12):3099–109. doi:10.1111/add.15987.
   PubMed Web of Science ®Google Scholar
• Psychedelics Legalization & Decriminalization Tracker. 2022. https://psychedelicalpha.com/data/psychedelic-laws.
   Google Scholar
• Rochester, J., A. Vallely, P. Grof, M. T. Williams, H. Chang, and K. Caldwell. 2021. Entheogens and psychedelics in Canada: Proposal for a new paradigm. Canadian Psychology/Psychologie Canadienne 63 (3):413–30. doi:10.1037/cap0000285.
   Web of Science ®Google Scholar
• Roseman, L., E. Haijen, K. Idialu-Ikato, M. Kaelen, R. Watts, and R. Carhart-Harris. 2019. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. Journal of Psychopharmacology 33 (9):1076–87. doi:10.1177/0269881119855974.
   PubMed Web of Science ®Google Scholar
• Schindler, E. A. D. 2022. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology 215:109166. doi:10.1016/j.neuropharm.2022.109166.
   PubMed Web of Science ®Google Scholar
• Tai, S. J., E. M. Nielson, M. Lennard-Jones, R.-L. Johanna Ajantaival, R. Winzer, W. A. Richards, F. Reinholdt, B. D. Richards, P. Gasser, and E. Malievskaia. 2021. Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. Frontiers in Psychiatry 12:586682. doi:10.3389/fpsyt.2021.586682.
   PubMed Web of Science ®Google Scholar
• Watts, R., and J. Luoma. 2019. The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science 15:92–102. doi:10.1016/j.jcbs.2019.12.004.
   Web of Science ®Google Scholar
• Zach, W., O. Merve Mollaahmetoglu, J. Rootman, S. Golsof, J. Keeler, B. Marsh, D. J. Nutt, and C. J. A. Morgan. 2021. Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open 8 (1):e19. doi:10.1192/bjo.2021.1061.
   PubMed Web of Science ®Google Scholar